Xeljanz (ZEL-jans, tofacitinib), a new ORAL treatment for moderate to severe rheumatoid arthritis in adults

You'll see Xeljanz (ZEL-jans, tofacitinib), a new ORAL treatment for moderate to severe rheumatoid arthritis in adults.

It's the first Janus kinase (JAK) inhibitor for RA. Janus kinase enzymes are linked to inflammation in joints and other tissues.

Xeljanz is approved to be added to methotrexate if needed...or used alone in patients who can't tolerate methotrexate.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote